Reimbursement ChallengesReimbursement payouts for TearCare are becoming more consistent, though not yet standardized.
Surgical Glaucoma BusinessThe surgical glaucoma business is expected to face headwinds through the remainder of the year, which management acknowledged is not something it can grow through until potentially the fourth quarter.
Tariffs ImpactTariffs are expected to be a ~$4M headwind, but management has begun to transition manufacturing outside of China over the next 9+ months.